Chronic pruritus is a subjective, multidimensional and highly impairing symptom of difficult assessment. Its clinical features and secondary burdens may vary substantially between affected individuals and within the same patient across time. Standardized scales and questionnaires have been developed to assess the various dimensions of chronic pruritus. Instruments addressing the intensity, distribution, qualities of associated symptoms, skin status and course over time are available for clinical trials. In addition, patient-oriented questionnaires on reactive conditions, including sleep disorders, anxiety, depression, and impairment of quality of life can be used. Assessing the individual patient's needs before and throughout the treatment is valuable in directing therapeutic priorities and maximizing patient's satisfaction. Along with a detailed medical history and a comprehensive physical examination, these instruments should be implemented in the clinical routine to achieve a comprehensive assessment of each patient. European experts of the European Academy of Dermatology and Venereology (EADV) considered a priority the use of intensity scales and questionnaires on quality of life. Harmonization of the assessment procedures should be aimed for across attending physicians. New technologies including electronic diaries or the use of tablet computers to complete assessment tools constitute helpful aids in the clinical practice by facilitating data collection and saving time.
Pruritus, defined as an unpleasant sensation inducing the need to scratch, is a subjective symptom and therefore difficult to measure in its multiple dimensions. Not only is the assessment of the pruritus itself relevant for the clinical practice and clinical trials, but also reactive conditions, such as sleep impairment, anxiety and depressive disorders, social reclusion, and impairment of the quality of life ( Table 1) . Because of the subjective nature of pruritus, its clinical characteristics and secondary conditions may drastically vary across patients even in those with similar pruritic conditions and may even fluctuate across the same patient in different time periods. In addition due to the plethora of dimensions associated with pruritus, a single measurement tool does not suffice for the proper assessment of the patient with pruritus. In fact several aspects should be taken into account when assessing a patient with pruritus: duration and trigger causes, intensity, quality and course over time of the symptom, impairment of quality of life, reactive disorders and skin lesions due to scratching. In order to answer all these questions, a combination of various instruments, preferably validated, should be standardized into the routine care of these patients. All these aspects contribute to the complex and challenging task of assessing pruritus [1] . Aim of this review article is to present the available instruments to measure the multiple dimensions of chronic pruritus and to suggest practical ways to make use of these instruments in the clinical routine and trials as well as discuss strategies to harmonize pruritus assessment across medical practitioners. An overview of the discussed assessment tools can be consulted in Table 2 .
Clinical features
Onset and duration of the pruritus One first important aspect to consider is for how long the patient is suffering from pruritus. If present for 6 weeks or more, pruritus is considered chronic (CP). This aspect has particular relevance for the diagnostic and therapeutic approach. The assessment tools reported in this review are to be used in patients suffering from CP.
The skin status at the beginning of the pruritic disease is also important to assess, especially whether the itch started on inflamed or normal appearing skin. In later stages, chronic scratch lesions as prurigo nodularis or lichen simplex chronicus may predominate and the original skin condition may not be detectable anymore [2] . Another important question is whether there was any relevant events associated with the initiation of the pruritic disease. Of importance are, for instance, the occurrence of eczemas, new medications, hospitalization or surgery, worsening of glycemia levels in case of diabetic patients or cholestasis parameters in liver disease. This information can mostly be obtained only retrospectively by history taking and is thus subject to recall bias. The identification of a triggering event may give important hints to the underlying etiology. According to the International Forum for the study of Itch (IFSI) CP can be caused by dermatological, neurological, systemic or psychiatric conditions, result from a combination of different diseases or be of unknown origin [2] . Identifying the underlying etiological factors for the itch is crucial for directing the therapeutic approach and thus achieve better results.
Intensity, quality, and distribution
The clinical characteristics of pruritus should be investigated thoroughly as they are crucial in determining the underlying cause. For example the concomitant presence of paresthetic symptoms, as for instance stinging, pricking or tingling, may suggest a neuropathic origin of the pruritus [3] , whereas pruritus accompanied by night-sweats in normal appearing skin may be caused by a Hodgkin lymphoma [4, 5] . Relevant characteristics of pruritus include its intensity, quality, distribution, alleviating and trigger factors, diurnal variation, and accompanying systemic symptoms. Standardized validated self-reported questionnaires are useful to assess these aspects. While the McGill Pain Questionnaire is well established and routinely used for chronic pain, a few options exist for CP [6] [7] [8] . These questionnaires should be validated for different pruritic conditions and in various languages in order to widen their use in the clinical routine.
Regarding pruritus intensity, three main scales have been validated for CP. In the visual analogue scale (VAS), patients are asked to mark on a 10-cm ruler ranging from 0 (no itch) to 10 (worst imaginable itch) how intense their pruritus is. In the numerical rating (NRS) 11 numbers from 0 to 10 are displayed and patients are asked to pick the number corresponding to the intensity of their pruritus. The verbal rating scale (VRS) is a 4 or 5-point Likert scale in which patients are asked to categorize their pruritus (eg, 0 = "no itch," 1 = "low itch," 2 = "moderate itch," 3 = "severe itch"). All these scales showed high reliability and correlation and are therefore valuable tools for the clinical routine [9] . These instruments are commonly used to measure pruritus at the moment of the assessment or the worst pruritus in the previous 24 hours or in the previous 4 weeks, but other time-points are also possible.
Course over time
Monitoring the course of the pruritus over time is valuable to evaluate the success of the treatment. Simple tools, as the dynamic pruritus score (DPS) [10] , and the 5-D itch scale [11] are available and can be used in clinical trials and routine care. Analogous to the Patient's Global Impression of Change used for pain conditions [12] , in the DPS patients are asked to assess the change in pruritus in percent in comparison with an earlier time-point (eg, begin of the treatment) on a visual scale. Scores range from − 100% (strongly worsened) to + 100% (almost no pruritus anymore) [10] . Interestingly, when comparing physician to patientbased assessments of DPS, patients seem to be less biased by a social desirability effect [13] . An alternative is the multidimensional 5-D itch scale, focusing as suggested by its name in 5 categories (degree, duration, direction, disability, distribution) [11] . This scale showed a strong correlation with the VAS and could detect significant changes in pruritus after treatment, while its score remained unchanged in untreated patients [11] . A validated physician reported tool for CP, as, for example, the Physician's Global Assessment used for psoriasis [14] , could be useful for assessing CP but it is still unavailable. The subjective nature of CP and lack of visible skin symptoms in all patients complicates the development of such an instrument.
Also useful for monitoring pruritus is the use of diaries. The daily assessment of the pruritus allows the identification of fluctuations between visits to the doctor. An electronic version of a pruritus-specific diary, the IchApp was developed and validated recently and can be accessed using a smartphone [15] .
Skin condition
Although pruritus is a subjective symptom, which cannot be assessed by objective tools, scratching lesions, when present, are visible and thus objectifiable. Attending physicians should Table 2 Overview of the pruritus assessment tools discussed in this article.
Category
Assessment Tool Being a multidimensional symptom, both the clinical features of chronic pruritus and the reactive disorders arising due to the pruritus should be taken into account in the management of these patients.
Pereira and Ständer. Itch (2019) 4:e29 Itch document the scratch lesions by describing them meticulously (number of lesions, size, morphology, distribution). Photographic documentation is also an option and allows the comparison of the skin condition over time with high precision. To measure scratching activity, a few tools such as accelerometers or actigraphy [16] are employed mainly in research settings but have not found yet application in the clinical practice. A novel app for smartwatches measuring nocturnal scratching showed a high reliability and a positive predictive value of 90% in a study enrolling patients with atopic dermatitis [17] . Actigraphy can thus be employed in the assessment of CP patients, but this instrument is of course of limited use in patients without scratch lesions.
Recently, the prurigo activity score (PAS) was developed to monitor patients affected by chronic prurigo over time. This instrument showed a good test-retest reliability and a high interrater reliability. The sensitivity of change for this tool should be investigated [18] .
Impairment of the quality of life
Special attention should be dedicated to CP patients in regard to impairment of their quality of life, as CP is one of the leading symptoms causing high burden [19] . In dermatology, the Dermatological Life Quality Index (DLQI), developed in 1994, is a validated instrument consisting of 10 questions addressing various issues, such as sensory symptoms, self-consciousness, interference with daily activities, work, sports and social life, sexual life and burden of the treatment. Since each item can be evaluated with a score varying from 0 (not at all) to 3 (very much), it is possible to obtain a total score ranging from 0 to 30. Scores of 11 or more are considered as a "very large effect on patient's life" [20] . Although this tool is frequently used in dermatology, it might not be useful for CP patients without dermatoses or chronic scratch lesions, as some of the questions focus on skin alterations and on the consequences thereof (eg, selfconsciousness, influence on clothing options). Therefore a pruritus-specific scale, Itchy-QoL was developed. This 22-question instrument covers several issues, including symptoms (eg, bleeding, pain, burning, lack of concentration), sleep impairment, body care, emotional aspects (eg, depression, frustration, self-esteem, self-control, catastrophizing), economic burden and impairment of the social life. Each item can be evaluated on a 5-point Likert scale from 0 (never) to 4 (all the time) [21] . This tool showed a good reliability, reproducibility and internal consistency, as well as responsiveness to clinical improvement [21] . Recently, an expert network on assessment of the severity and burden of pruritus of the European Academy of Dermatology and Venereology (EADV) highlighted the importance of pruritus-specific tools for measuring quality of life and emphasized the urgency in validating them [22] . Many other nondermatological instruments to assess diseaserelated impairment of quality of life exist and may also be used to evaluate CP patients.
Reactive disorders

Sleep disorders
As in many other chronic conditions, secondary disorders represent a high burden to the affected individuals. Pruritus is often perceived more intensely in the evening and at night when patients are no longer distracted with daytime activities, which may lead to sleep impairment. Both difficulties in falling asleep and premature awakenings due to the pruritus are often reported [23] . No pruritus-specific scales for sleep impairment are yet available. However, general scales, including the Stanford Sleepiness Scale, the Epworth Sleepiness Scale and the Athens Insomnia Scale can be used. The Stanford Sleepiness Scale, comprising a rating from 1 to 7 (1 = "feeling active, vital, alert, or wide awake"; 7 = "no longer fighting sleep, sleep onset soon, having dream-like thoughts") permits a swiftly assessment of the degree of alertness [24] . The Epworth Sleepiness Scale is an 8-item questionnaire also measuring alertness. Each item can be evaluated in a scale from 0 (would never doze) to 3 (high chance of dozing) with scores ≥ 11 representing enhanced levels of daytime sleepiness [25] . The Athens Insomnia Scale consists of 8 items assessing sleep quality and duration, sleep induction, awakening at night, daytime alertness, general well-being, and functional impairment. It has established itself as a reliable tool for screening for insomnia [26, 27] . Other instruments as the Pittsburgh Sleep Quality Index [28] or pictorial scales for children [29] may also be considered in the assessment of pruritus associated sleep impairment.
Anxiety and depression
Pruritus and the consequences thereof, as sleep impairment, social reclusion, visible scratching lesions, may induce anxiety and depressive disorders in the affected individuals. A useful screening tool is the Hospital Anxiety and Depression Scale. This validated scale introduced in 1983 consists of 2 subscales screening for anxiety and depression, each containing 7 items and a maximum score of 21. Scores of 11 or higher indicate a possible disorder and patients should be directed to a psychiatrist or psychologist for further assessment [30, 31] . To assess the severity of a possible depression the Beck Depression Inventory may be also suitable. Consisting of 21 questions, this self-report questionnaire assesses feelings of hopelessness, guilt, irritability, punishment, as well as physical symptoms, as weight loss or tiredness [32, 33] . The Hamilton Rating Scale for Depression is an alternative screening tool for depression. It is a more comprehensive instrument, analyzing depressed moods, suicide ideation, insomnia, feelings of guilt, agitation, anxiety, somatic symptoms, impairment in productivity, psychomotor retardation, depersonalization, paranoia, and obsession [34] . Many other tools to screen for depression and anxiety are available and may have more applicability in specific contexts (eg, the Geriatric Depression Scale [35] in the elderly). Nevertheless pruritus-specific tools are still lacking. Because of the singularities of CP an effort to develop specific screening tools for reactive depression and anxiety would be desirable.
In addition other psychological parameters such as coping and catastrophizing play an important role in patients with CP. For assessment, different questionnaires depending on the issue are applicable next to an interview by a specialist. For example, the Itching Cognitions Questionnaire consists of 2 subscales assessing catastrophizing and coping. This instrument proved to be valid and reliable and is available in German, Dutch and Japanese [36] . However, a comprehensive overview on the different psychological problems and their assessment shall be addressed in a separate review.
Patient needs and benefits
Expectations and goals toward the therapy may vary considerably across patients with CP. These should be taken into account when planning the treatment to achieve higher degrees of satisfaction. Importantly needs may vary according to the underlying cause of the pruritus, to whether scratch lesions are present or across gender [37] . Issues around non-responding populations in clinical trials can be better isolated by reviewing their treatment aims and potential benefit gaps. The Patient Benefit Index for pruritus (PBI-P), a questionnaire addressing 27 potential treatment benefits, was developed and validated for CP [38, 39] . In this self-reported questionnaire, each item is evaluated using a 5-point Likert scale ranging from 0 (not important at all or does not apply to me) to 4 (very important). Various aspects are covered, including daily activities, physical and mental well-being, work performance, leisure undertakings, and social life. Before the treatment, patients are asked to complete the so-called Patient Needs Questionnaire (PNQ), in order to determine the relevance of each therapeutic goal for the individual patient. In follow-up visits, after the treatment has been initiated, patients are asked to fill out the Patient Benefit Questionnaire (PBQ). As a result of these 2 assessment forms, the individual benefit for each patient (PBI) can be calculated. The PBI is of high value for the clinical practice, since it allows patients and physicians to cooperate in defining the individual goals for each case and to develop accordingly a targeted therapeutic strategy.
Discussion
Because of the multidimensional nature of CP, its assessment is complex and time-consuming. To date no consistent metric instruments objectifying CP are yet available. Patient-reported outcomes are of great relevance, as CP is a subjective symptom perceived differently in its various dimensions by each patient. Standardized scales and questionnaires facilitate this process and contribute ultimately to a better care. However, these instruments should be used sensibly and not substitute a detailed medical history and a comprehensive physical examination.
Although there is now a multitude of instruments to assess the different dimensions of CP, there is still a lack of harmonization on which tools to use in the clinical practice or in clinical trials across different countries or even across centers of the same country. This complicates the comparison of data between centers, impairing CP management. In addition the clinical utility of the available instruments should be investigated, as data on this matter is scarce. International expert consensus is thus needed to harmonize proceedings. The first steps have been given by a European network of specialists in CP associated with the EADV, which reached a consensus on CP assessment in dermatological routine care. The pruritus intensity and the impact on quality of life were considered the 2 most relevant aspects [22] . For the pruritus intensity, the VAS was regarded as the most valuable tool [22] . Alternatively, the NRS or the VRS are also valid options. Regarding the burden of the disease, experts recommend the use of the ItchyQol. In case of dermatoses the DLQI also constitutes a good alternative [22] . These scales should be validated in different languages in order to be introduced in the clinical routine in each country.
Recently, the Chronic Pruritus Tools Questionnaire (Pruritools) gathering a set of tools (intensity scales, assessment of sensory qualities, responsiveness over time to therapy) was developed showing satisfactory validity and reliability. This tool allows a comprehensive assessment of itch in a short time and may be practical to use in routine care or in clinical studies [40] .
The comprehensive assessment of CP is time-consuming, which constitutes a problem in today's era of economic constraints. Using the available assessment instruments a highvolume of information is gained in a short period of time. While some tools, as the Patient Needs Questionnaire or a standardized questionnaire on the clinical aspects of itch (eg, the AGP questionnaire [7] ) are designed for the initial visit only, other tools are useful in the follow-up visits as they are designed to analyze itch related parameters over time and the response to therapy (Fig. 1) .
In the clinical routine, assessment scales and questionnaires can be completed before the doctor's visit in the waiting room. If only a subset of scales can be completed (for instance due to time constraints) we suggest prioritizing the use of itch intensity scales, as itch-VAS or itch-NRS, and the ItchyQol. In addition at the first visit a questionnaire on the clinical features of the disease such as the American Itch Questionnaire (in English) [8] or the AGP Questionnaire [7] (in German) is useful. If available in an electronic format, these instruments can be filled out for instance on a tablet or a computer. This enables the immediate transfer of information to the physician's electronic information system. As the patient enters the office, the attending physician has already an overview of the patient's situation, saving precious time.
Data collection is, however, not only limited to the doctor's office. For a comprehensive monitoring of the pruritus over time, diaries are useful tools. Patient-oriented electronic diaries specific for pruritus [15] represent an advantage in comparison to paperbased diaries, since data can be readily transferred to the physician's electronic system, facilitating the monitoring of the symptom between visits.
A limitation of some of the available instruments is that quality parameters have not been systematically investigated, especially regarding its validity, reliability, and sensitivity to change over the course of a therapy. Such quality indicators are of relevance when choosing which tools should be recommended for the clinical routine. Future studies should focus on analyzing the quality of already available instruments in the context of chronic itch.
Conclusions
Standardized instruments are valuable for the assessment of the various dimensions of CP and should be used in the clinical routine along with a detailed medical history and a comprehensive physical examination. Harmonization of proceedings across itch centers and dermatological offices should be aimed for in order to elevate standards and facilitate comparison of data. In addition, modern technologies constitute important aids in the assessment of CP and should be implemented in the daily practice. 
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